Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Sanofi Rheumatoid Arthritis Drug Cuts Pain, Damage in Study

Nov. 22 (Bloomberg) -- Sanofi and Regeneron Pharmaceuticals Inc.’s experimental rheumatoid arthritis drug eased symptoms and damage caused by the disease in a clinical trial, advancing its prospects to compete in a market led by Roche Holding AG.

In a study of 1,200 patients for whom the standard treatment methotrexate wasn’t sufficient, sarilumab plus methotrexate eased pain and stiffness twice as much as those who got methotrexate alone, and slowed joint destruction 90 percent more, the two companies said in a joint statement today.

The trial is one of two that Paris-based Sanofi plans to use to seek regulatory approval for sarilumab. The drug may generate sales of 579 million euros ($780 million) by 2020, according to the average of four analyst estimates compiled by Bloomberg. It would compete with Roche’s Actemra and other experimental treatments in development by AbbVie Inc., Johnson & Johnson and Bristol-Myers Squibb Co.

“These are solid but not particularly exciting results,” Olav Zilian and Odile Rundquist, analysts with Helvea SA in Geneva, wrote in a note today. The drug “will come several years late to the market that is led by Roche’s Actemra.”

Regeneron gained 6.3 percent to $293.68 at the close in New York. The shares have advanced 72 percent this year. Sanofi fell less than 1 percent to 78.13 euros at the close in Paris. The shares have returned 13 percent this year, including reinvested dividends.

The study evaluated three groups of patients who received, in combination with methotrexate, either a 200 milligram or 150 milligram dose of sarilumab, or placebo. Among those in the study receiving the highest dose of sarilumab, 14 percent withdrew from the trial because of side effects, compared with 5 percent of those on methotrexate alone. Infections were also more common among those on Sanofi’s drug.

The results were from the last of three stages of human tests generally required for regulatory approval.

Joint Inflammation

Rheumatoid arthritis causes inflammation of the joints, often in the hands and feet. It is thought to be caused by problems with the immune system, according to the U.S. Centers for Disease Control and Prevention in Atlanta. About 1.5 million people in the U.S. have it, according to the Arthritis Foundation.

Patients typically start treatment with methotrexate, a cheaply available generic drug. If methotrexate doesn’t work or becomes less effective, doctors can add a therapy such as AbbVie’s best-selling drug Humira or Pfizer Inc.’s Enbrel. There’s no cure for the chronic disease.

Sanofi gained sarilumab as part of an alliance with the Tarrytown, New York-based biotechnology company Regeneron, in which it owns a 17 percent stake.

The drug targets a messenger protein called interleukin-6, or IL-6, that is over-produced by people with rheumatoid arthritis, contributing to joint damage and inflammation.

Basel, Switzerland-based Roche’s Actemra generated $898 million in sales last year. AbbVie is developing a drug that targets IL-6, called ALX-0061, which it licensed from Ghent, Belgium-based Ablynx NV in September in a deal worth as much as $840 million. Johnson & Johnson’s drug is called sirukumab and Bristol-Myers’ is called clazakizumab.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.